Rasio Total Utang marang Ekuitas Creative Medical Technology Holdings Inc. (CELZ)

Creative Medical Technology (CELZ) specializes in regenerative male health treatments utilizing AmnioStem cellular products. This price chart from GURU.Markets demonstrates a debt-to-equity ratio of 0.00. The company's monopoly pricing power is bolstered by the implementation of automated bioreactors to eliminate human error, as well as the ownership of unique patents in the field of immunomodulation.

Creative Medical Technology Holdings Inc. - Utang marang Modal CELZ (periode 04.07.2022 - 27.10.2026)

Rincian analitis lan laporan data perusahaan Creative Medical Technology Holdings (CELZ)

- rega lan prakiraan konsensus rega:

Bagan rega Creative Medical Technology Holdings, Inc.|CELZ - Target median analis

- data kapitalisasi pasar:

Biji pasar Creative Medical Technology|CELZ - Total Nilai Bisnis

- data kapitalisasi buku:

Nilai Buku saben Saham Creative Medical Technology|CELZ - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku creativemedicaltechnology.com|CELZ - Gunggung Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Creative Medical Technology|CELZ - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Creative Medical Technology Holdings, Inc.|CELZ - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Creative Medical Technology

Ringkesan analisis perusahaan:CELZ, Creative Medical Technology

Produk merek Creative Medical Technology Holdings

To minimize capital loss risks amid volatility, investors must analyze the total debt-to-equity ratio, which measures the proportion of borrowed funds relative to the company's own resources to assess financial leverage. This metric determines the balance sheet resilience of Creative Medical Technology (CELZ) to rising Fed rates, which is critical for a venture business in the non-cyclical cell therapy sector.

Pesaing wigati